For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no ...

Pfizer (PFE) closed the most recent trading day at $26.91, moving -0.83% from the previous trading session. This change lagged the S&P 500's 0.16% gain on the day. Meanwhile, the Dow experienced a ...

FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk.

Notable medicines subject to price increases include Pfizer’s COVID-19 drug Paxlovid, Bristol Myers Squibb’s CAR-T therapies Abecma and Breyanzi and a clutch of vaccines from Sanofi ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. Pfizer’s decision sent ...

Sangamo Therapeutics (NASDAQ:SGMO) lost nearly half of its market cap in early trading on Tuesday after Pfizer (NYSE:PFE) decided to end a collaboration with the company for its gene therapy ...

Strong performance in oncology and specialty products is fueling new growth at Pfizer. The stock's 6.3% dividend is well-funded, and management has just increased it. The bar is low for ...

Pfizer Inc. defeated a lawsuit from Texas Attorney General Ken Paxton that alleged the pharmaceutical giant misrepresented the effectiveness of its Covid-19 vaccine. Pfizer is entitled to immunity ...

Dec 30 (Reuters) - Sangamo Therapeutics (SGMO.O), opens new tab said on Monday that partner Pfizer (PFE.N), opens new tab has terminated their hemophilia A gene therapy co-development agreement ...

PF-07976016 is under clinical development by Pfizer and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication ...

They even generated clinical results that suggested it might have promise as a weight-loss drug as well — only to have Pfizer, which had agreed to fund the research, withdraw its support ...